The epidemiology of myasthenia gravis

J Med Life. 2021 Jan-Mar;14(1):7-16. doi: 10.25122/jml-2020-0145.

Abstract

Neuromuscular junction (NMJ) disorders include several dysfunctions that ultimately lead to muscle weakness. Myasthenia gravis (MG) is the most prevalent NMJ disorder with a highly polymorphic clinical presentation and many different faces. Being an autoimmune disease, MG correlates with the presence of detectable antibodies directed against the acetylcholine receptor, muscle-specific kinase, lipoprotein-related protein 4, agrin, titin, and ryanodine in the postsynaptic membrane at the NMJ. MG has become a prototype serving to understand both autoimmunity and the function of the NMJ better. The aim of this review is to synthesize some of the epidemiological data available. Epidemiological data regarding MG are important for postulating hypotheses regarding its etiology and facilitating the description of MG subtypes. Thus, adequate documentation through broad databases is essential. The incidence and prevalence of MG reported around the globe have been rising steadily and consistently over the past decades. Ethnic aspects, gender-related differences, and environmental risk factors have been described, implying that these might contribute to a specific phenotype, further suggesting that MG may be considered an umbrella term that covers several clinical entities.

Keywords: autoimmunity; epidemiology; incidence; myasthenia gravis; prevalence.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Genetic Predisposition to Disease
  • Humans
  • Incidence
  • Myasthenia Gravis / epidemiology*
  • Myasthenia Gravis / genetics
  • Myasthenia Gravis / immunology
  • Myasthenia Gravis / physiopathology
  • Prevalence
  • Risk Factors